Actuate TherapeuticsACTU +6.71%14 Debt-to-EBITDA is 0.00 as of Mar. 2026. GuruFocus rates ACTU with a GF Score™ of 14/100. Among 290 Biotechnology companies, Actuate Therapeutics ranks worse than 344827.24% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Actuate Therapeutics's Debt-to-EBITDA or its related term are showing as below:
ACTU's Debt-to-EBITDA is not ranked *
in the Biotechnology industry.
Industry Median: 1.15 * Ranked among companies with meaningful Debt-to-EBITDA only.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Actuate Therapeutics Debt-to-EBITDA Related Terms
Actuate Therapeutics Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Actuate Therapeutics's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ACTU vs RNXT, ESLA, APLM: Debt-to-EBITDA Comparison
For the Biotechnology subindustry, Actuate Therapeutics's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Actuate Therapeutics Debt-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Actuate Therapeutics's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Actuate Therapeutics's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
Actuate Therapeutics (ACTU) has a Debt-to-EBITDA of 0.00 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Actuate Therapeutics. According to the industry distribution chart, Actuate Therapeutics ranks #999999 out of 290 companies in the Biotechnology industry.
Is Actuate Therapeutics' Debt-to-EBITDA too high?
Actuate Therapeutics' current Debt-to-EBITDA is 0.00. Based on the distribution chart, Actuate Therapeutics ranks #999999 out of 290 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Actuate Therapeutics has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Actuate Therapeutics' Debt-to-EBITDA compare to RNXT and ESLA?
According to the Biotechnology industry distribution chart, Actuate Therapeutics ranks #999999 out of 290 companies for Debt-to-EBITDA. This places Actuate Therapeutics in the lower half of its industry. The industry median Debt-to-EBITDA is 1.15. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Biotechnology company?
The median Debt-to-EBITDA among Biotechnology companies is 1.15, based on 290 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Actuate Therapeutics. For the Biotechnology industry, the median Debt-to-EBITDA is 1.15 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Actuate Therapeutics's current Debt-to-EBITDA is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Actuate Therapeutics stock overvalued right now?
Actuate Therapeutics (ACTU) has a current Debt-to-EBITDA of 0.00. The current Debt-to-EBITDA is 0.00. Actuate Therapeutics' overall GF Score™ is 14/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Actuate Therapeutics (ACTU), the current Debt-to-EBITDA is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Actuate Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). It is developing elraglusib (formerly 9-ING-41), a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3B, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, that lead to tumor cell survival, growth, migration, and invasion.
14GF Score
Get the complete analysis for ACTU
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ACTU has been successfully added to your 
